Back to search results

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer (Adenocarcinoma) · mCRPC (Metastatic Castration-resistant Prostate Cancer)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Erin Morones) · emorones@coh.org · 626-218-9708

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Alicia Morgans, MD) · aliciak_morgans@dfci.harvard.edu · 857-215-1605

  • Masonic Cancer Center, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Masonic Cancer Nurse Line) · ccinfo@umn.edu

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Karen Autio, MD) · autiok@mskcc.org · 646-422-4632

  • Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Alex Torres) · alexandra.torres@pennmedicine.upenn.edu · 267-496-7621

  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Steven Blinka, MD) · sblinka@fredhutch.org
    Contact: Study coordinator (Lara Wahid) · lwahid@fredhutch.org
    Contact: Principal Investigator (Steven Blinka, MD)

  • University of Wisconsin Carbone Cancer Center-Madison, Madison, Wisconsin, United States

    Contact: Study coordinator (UWCCC Clinical Trials Navigation Team) · clinicaltrials@cancer.wisc.edu · 608-262-0439
Study leads

  • Alicia Morgans, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)